Table of Contents

November 2017 • Volume 15 • Number 11

Molecular Cancer Research

Highlights of This Issue 1467

CELL DEATH AND SURVIVAL

1469 Targeting AR Variant–Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities
Fiorella Magani, Stephanie O. Peacock, Meghan A. Rice, Maria J. Martinez, Ann M. Greene, Pablo S. Magani, Rolando Lyles, Jonathan R. Weitz, and Kerry L. Burnstein

1481 Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/b-catenin Signaling
Georg Emons, Melanie Spitzner, Sebastian Reineke, Janneke Moller, Noam Auslander, Frank Kramer, Yue Hu, Tim Beissbarth, Hendrik A. Wolff, Margret Rave-Frank, Elisabeth Hefmann, Jochen Gaedcke, B. Michael Ghadimi, Steven A. Johnsen, Thomas Ried, and Marian Grade

CHROMATIN, EPIGENETICS, AND RNA REGULATION

1491 Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ER-negative Breast Cancers to Tamoxifen through ERα Reexpression
Muralidharan Anbalagan, Mei Sheng, Brian Fleischer, Yifang Zhang, Yuanjun Gao, Van Hoang, Margarite Matossian, Hope E. Burks, Matthew E. Burow, Bridgette M. Collins-Burow, David Hangauer, and Brian G. Rowan

DNA DAMAGE AND REPAIR

1503 EGFR Mutations Compromise Hypoxia-Associated Radiation Resistance through Impaired Replication Fork–Associated DNA Damage Repair
Mohammad Saki, Haruhiko Makino, Prashanthi Javvadi, Nozomi Tomimatsu, Liang Hao Ding, Jennifer E. Clark, Elaine Gavrin, Kenichi Takeda, Joel Andrews, Dehabrata Saha, Michael D. Story, Sandeep Burma, and Chaitanya S. Nirodi

METABOLISM

1517 EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma
Jason M. Tanner, Claire Bensard, Peng Wei, Nathan M. Krah, John C. Schell, Jamie Gardiner, Joshua Schifman, Stephen L. Lessnick, and Jared Rutter

 genotype

1531 CDK4/6 Inhibition on Glucose and Pancreatic Beta Cell Homeostasis in Young and Aged Rats
Aida I. Sacan, Stephane Thibault, Miyou Y. Hong, Nagesha G. Kondegowda, Tim Nichols, Rosemary Li, Carolina Rosselot, Winston Evering, Rafael Fenuitria, Allison Vitsky, Thomas Brown, Martin Finkelstein, Adolfo Garcia-Ocaña, Nasir Khan, Andrew F. Stewart, and Rupangi C. Vasavada

GENOMICS

1542 Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal
Van Morris, Xiayu R. Xu, Curtis Pickering, Wai Chin Foo, Asif Rashid, Karina Eterovic, Taeboom Kim, Ken Chen, Jing Wang, Kenna Shaw, and Cathy Eng

1551 Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications
Lorena Lazo de la Vega, Jonathan B. McHugh, Andi K. Cani, Komal Kunder, Frances M. Wosock, Chia-Jen Liu, Daniel H. Hovelson, Dan Robinson, Arul M. Chinnaian, Scott A. Tomlins, and Paul W. Harms

1558 Novel Aberrations Uncovered in Barrett’s Esophagus and Esophageal Adenocarcinoma Using Whole Transcriptome Sequencing

ONCOGENES AND TUMOR SUPPRESSORS

1570 miR-432 Induces NRF2 Stabilization by Directly Targeting KEAP1
Burak Akdemir, Yasuaki Nakajima, Jochi Inazawa, and Jun Inoue

1579 Nuclear Envelope Rupture Is Enhanced by Loss of p53 or Rb
Zhe Yang, John Maciejowski, and Titia de Lange
Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity
Corina N.A.M. van den Heuvel, Anna C. Navis, Tessa de Bitter, Houshang Amiri, Kiek Verrijp, Arend Heerschap, Karen Rex, Isabelle Dussault, Sean Caenepeel, Angela Coxon, Paul N. Span, Pieter Wesseling, Wiljan Hendriks, and William P.J. Leenders

Early-Stage Metastasis Requires Mdm2 and Not p53 Gain of Function

ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling
Roopali Roy, Adelle Dagher, Catherine Butterfield, and Marsha A. Moses

Heparan Sulfate Glycosaminoglycans in Glioblastoma Promote Tumor Invasion

The cover image depicts chromosomal copy alterations detected by next generation sequencing in olfactory neuroblastomas—rare, highly aggressive tumors of the sinonasal cavity. In this issue, Lazo de la Vega and colleagues (beginning on page 1551) demonstrate that olfactory neuroblastomas are characterized by recurrent chromosomal numerical alterations, including amplifications of the potential oncogenic driver FGFR3 in a subset. The finding suggests that FGFR3 may be a rational therapeutic target in olfactory neuroblastoma.